GFP Adeno-Associated Virus ( AAV-NSSRDLG )

To successfully perform gene transduction, AAV vectors must overcome multiple biological barriers that limit transgene delivery. The first step in cellular transduction is attachment of the vector to one or more cell surface receptors or coreceptors, followed by uptake of the capsid-receptor complex via endocytosis. To date, several potential pathways for cellular trafficking of rAAV2 vectors have been described, all consistent with viral particles being taken up into endosomal compartments following internalization. During endosomal trafficking, the viral capsid undergoes conformational changes that result in exposure of the hidden VP1/VP2 N-terminal domains, which are critical for efficient transduction.

GFP AAV-NSSRDLG particles are derived from AAV serotype 2 (AAV2), a well-studied serotype commonly used in gene therapy due to its high transduction efficiency and low immunogenicity. The key modification in AAV-NSSRDLG is the insertion of the peptide sequence NSSRDLG at position I588 of the viral capsid. This strategic insertion is designed to specifically target endothelial cells, making it a valuable tool for studying vascular biology, cardiovascular disease, and endothelial cell function and pathology.